ATE553206T1 - Expression von genen mit überlappenden offenen leserastern in insektenzellen, verfahren und zusammensetzungen dafür - Google Patents
Expression von genen mit überlappenden offenen leserastern in insektenzellen, verfahren und zusammensetzungen dafürInfo
- Publication number
- ATE553206T1 ATE553206T1 AT07814439T AT07814439T ATE553206T1 AT E553206 T1 ATE553206 T1 AT E553206T1 AT 07814439 T AT07814439 T AT 07814439T AT 07814439 T AT07814439 T AT 07814439T AT E553206 T1 ATE553206 T1 AT E553206T1
- Authority
- AT
- Austria
- Prior art keywords
- insect cells
- methods
- open reading
- gene
- genes
- Prior art date
Links
- 241000238631 Hexapoda Species 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title 1
- 108700026244 Open Reading Frames Proteins 0.000 abstract 2
- 241000702421 Dependoparvovirus Species 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00041—Use of virus, viral particle or viral elements as a vector
- C12N2750/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/103—Plasmid DNA for invertebrates
- C12N2800/105—Plasmid DNA for invertebrates for insects
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/50—Vectors for producing vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83976106P | 2006-08-24 | 2006-08-24 | |
| PCT/US2007/076799 WO2008024998A2 (en) | 2006-08-24 | 2007-08-24 | Expression in insect cells of genes with overlapping open reading frames, methods and compositions therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE553206T1 true ATE553206T1 (de) | 2012-04-15 |
Family
ID=39107735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07814439T ATE553206T1 (de) | 2006-08-24 | 2007-08-24 | Expression von genen mit überlappenden offenen leserastern in insektenzellen, verfahren und zusammensetzungen dafür |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US8945918B2 (de) |
| EP (1) | EP2061891B1 (de) |
| CN (1) | CN101522903B (de) |
| AT (1) | ATE553206T1 (de) |
| DK (1) | DK2061891T3 (de) |
| ES (1) | ES2385679T3 (de) |
| WO (1) | WO2008024998A2 (de) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009215987B2 (en) * | 2008-02-19 | 2015-01-22 | Uniqure Ip B.V. | Optimisation of expression of parvoviral rep and cap proteins in insect cells |
| US8734780B2 (en) | 2010-06-04 | 2014-05-27 | Medtronic, Inc. | Methods for treating cardiac pacing conditions |
| AU2012348332B2 (en) | 2011-12-08 | 2017-06-29 | Haifeng Chen | Vectors harboring toxic genes, methods and uses therefor |
| ES2628006T3 (es) | 2012-02-21 | 2017-08-01 | Circuit Therapeutics, Inc. | Composiciones para el tratamiento de trastornos neurogénicos del suelo pélvico |
| TWI698240B (zh) | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| CA2894718A1 (en) | 2012-11-21 | 2014-05-30 | Circuit Therapeutics, Inc. | System and method for optogenetic therapy |
| ES2742492T3 (es) | 2013-03-15 | 2020-02-14 | Univ Leland Stanford Junior | Control optogenético del estado conductual |
| US10220092B2 (en) | 2013-04-29 | 2019-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | Devices, systems and methods for optogenetic modulation of action potentials in target cells |
| JP6621747B2 (ja) | 2013-08-14 | 2019-12-18 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 疼痛を制御するための組成物及び方法 |
| EP3666287A1 (de) | 2013-12-31 | 2020-06-17 | ProteoNic Biotechnology IP B.V. | Konstrukt und sequenz zur verbesserten genexpression |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| ES2822551T3 (es) | 2014-03-17 | 2021-05-04 | Adverum Biotechnologies Inc | Composiciones y métodos para la expresión génica mejorada en células de los conos |
| US10612041B2 (en) | 2014-03-21 | 2020-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Genome editing without nucleases |
| EP3581580A1 (de) | 2014-03-28 | 2019-12-18 | The Board of Trustees of the Leland Stanford Junior University | Manipulierte lichtaktivierte anionenkanalproteine und verfahren zur verwendung davon |
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| EP3215191B1 (de) | 2014-11-05 | 2024-08-14 | Voyager Therapeutics, Inc. | Aadc-polynukleotide zur behandlung von morbus parkinson |
| CN114717264A (zh) | 2014-11-14 | 2022-07-08 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
| KR20230145206A (ko) | 2014-11-14 | 2023-10-17 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
| FI3265178T3 (fi) | 2015-03-02 | 2026-08-03 | Adverum Biotechnologies Inc | Koostumuksia ja menetelmiä polynukleotidien viemiseksi intravitreaalisesti retinaalisiin tappisoluihin |
| JP6836999B2 (ja) | 2015-03-24 | 2021-03-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | アデノ随伴ウイルス変異体及びその使用方法 |
| CA2999279A1 (en) | 2015-10-01 | 2017-04-06 | Goleini Inc. | Targeted expression of chloride channels and methods of use thereof |
| US10406244B2 (en) | 2015-12-02 | 2019-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | AAV vectors with expanded packaging capacity |
| WO2017096164A1 (en) | 2015-12-02 | 2017-06-08 | The Board Of Trustees Of The Leland Stanford Junior University | Novel recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism |
| GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
| CA3014637A1 (en) | 2016-02-16 | 2017-08-24 | Mark A. Kay | Novel recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies |
| CA3012699C (en) | 2016-04-21 | 2023-11-21 | Virovek, Inc | Aav production in insect cells, methods and compositions therefor |
| EP3448987A4 (de) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | Zusammensetzungen zur behandlung einer erkrankung |
| EP3448874A4 (de) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | Zusammensetzungen zur behandlung einer erkrankung |
| US10584337B2 (en) | 2016-05-18 | 2020-03-10 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| IL297576B2 (en) | 2016-05-18 | 2024-02-01 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
| EP3831281B1 (de) | 2016-08-30 | 2026-02-25 | The Regents of The University of California | Vorrichtungen und systeme für biomedizinische zielführung und verabreichung |
| US11773409B2 (en) | 2017-04-21 | 2023-10-03 | The Board Of Trustees Of The Leland Stanford Junior University | CRISPR/Cas 9-mediated integration of polynucleotides by sequential homologous recombination of AAV donor vectors |
| MX2019013172A (es) | 2017-05-05 | 2020-09-07 | Voyager Therapeutics Inc | Composiciones y metodos para tratar la enfermedad de huntington. |
| EP3618839A4 (de) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | Zusammensetzungen und verfahren zur behandlung von amyotropher lateralsklerose (als) |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| US11452749B2 (en) | 2017-07-10 | 2022-09-27 | Uniqure Ip B.V. | Means and methods for AAV gene therapy in humans |
| CA3070087A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | Trajectory array guide system |
| MX2020001593A (es) | 2017-08-09 | 2020-07-13 | Bioverativ Therapeutics Inc | Moleculas de acido nucleico y usos de las mismas. |
| MX2020003042A (es) | 2017-09-29 | 2020-11-18 | Voyager Therapeutics Inc | Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa. |
| US20200231986A1 (en) * | 2017-09-29 | 2020-07-23 | Massachusetts Eye And Ear Infirmary | Production of adeno-associated viruses in insect cells |
| TW202413649A (zh) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| JP7389040B2 (ja) | 2018-01-17 | 2023-11-29 | メイラジーティーエックス・ユーケー・ザ・セカンド・リミテッド | 遺伝子治療のための修飾ｒＡＡＶキャプシドタンパク質 |
| EP3774853A1 (de) | 2018-03-30 | 2021-02-17 | The Board of Trustees of the Leland Stanford Junior University | Neuartige kapside des rekombinanten adeno-assoziierten virus mit erhöhtem menschlichem pankreatischem tropismus |
| CN112424359A (zh) | 2018-05-15 | 2021-02-26 | 沃雅戈治疗公司 | 用于治疗帕金森氏病的组合物和方法 |
| WO2019237375A1 (zh) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | 一种将hdmx基因定点整合至mcf-7细胞的方法及其应用 |
| JP7602454B2 (ja) | 2018-08-09 | 2024-12-18 | バイオベラティブ セラピューティクス インコーポレイテッド | 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用 |
| US12281321B2 (en) | 2018-09-28 | 2025-04-22 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| CN113166208B (zh) | 2018-10-02 | 2024-11-22 | 沃雅戈治疗公司 | 重新定向aav衣壳的嗜性 |
| AU2019354793A1 (en) * | 2018-10-05 | 2021-05-13 | Voyager Therapeutics, Inc. | Engineered nucleic acid constructs encoding AAV production proteins |
| CN119390787A (zh) | 2019-01-31 | 2025-02-07 | 俄勒冈健康与科学大学 | 用于aav衣壳的使用转录依赖性定向进化的方法 |
| KR20210126096A (ko) | 2019-02-15 | 2021-10-19 | 상가모 테라퓨틱스, 인코포레이티드 | 재조합 aav를 제조하기 위한 조성물 및 방법 |
| CN114450411A (zh) | 2019-04-01 | 2022-05-06 | 特纳亚治疗股份有限公司 | 具有工程化衣壳的腺相关病毒 |
| JP7664848B2 (ja) | 2019-04-10 | 2025-04-18 | プリベイル セラピューティクス，インコーポレーテッド | リソソーム障害のための遺伝子療法 |
| HRP20251506T1 (hr) | 2019-04-10 | 2026-01-02 | Prevail Therapeutics, Inc. | Genska terapija za lizosomske poremećaje |
| US10653731B1 (en) | 2019-07-15 | 2020-05-19 | Vigene Biosciences Inc. | Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency |
| US10801042B1 (en) | 2019-07-15 | 2020-10-13 | Vigene Biosciences, Inc. | Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus |
| US10557149B1 (en) | 2019-07-15 | 2020-02-11 | Vigene Biosciences, Inc. | Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus |
| SMT202400486T1 (it) | 2019-07-15 | 2025-01-14 | Meiragtx Uk Ii Ltd | Proteine di capside avv modificate per il trattamento della malattia artritica |
| AU2020316034A1 (en) | 2019-07-23 | 2022-02-10 | Janssen Biotech, Inc. | Synthetic genetic elements for biomanufacture |
| US20230020565A1 (en) | 2019-12-04 | 2023-01-19 | Sangamo Therapeutics, Inc. | Novel compositions and methods for producing recombinant aav |
| CN111004803B (zh) * | 2019-12-31 | 2023-05-16 | 中山大学 | 褐飞虱NlStit基因作为靶点在制备防治褐飞虱药物中的应用 |
| AU2021250656A1 (en) | 2020-04-02 | 2022-09-15 | Uniqure Biopharma B.V. | Dual bifunctional vectors for AAV production |
| CN115867647A (zh) | 2020-04-02 | 2023-03-28 | 优尼科生物制药有限公司 | 新型细胞系 |
| US12630842B2 (en) | 2020-05-13 | 2026-05-19 | Voyager Therapeutics, Inc. | Redirection of tropism of AAV capsids |
| AU2021325891A1 (en) | 2020-08-10 | 2023-04-06 | Prevail Therapeutics, Inc. | Gene therapies for neurodegenerative disorders |
| CN116157527A (zh) | 2020-08-10 | 2023-05-23 | 普利维尔治疗公司 | 用于溶酶体病症的基因疗法 |
| JP7415042B2 (ja) | 2020-10-09 | 2024-01-16 | テナヤ セラピューティクス， インコーポレイテッド | プラコフィリン２遺伝子治療の方法および組成物 |
| CN112852882A (zh) * | 2021-02-04 | 2021-05-28 | 中吉智药(南京)生物技术有限公司 | 一种杆状病毒感染昆虫细胞生产aav基因药物的系统及方法 |
| EP4301861A1 (de) | 2021-03-03 | 2024-01-10 | Shape Therapeutics Inc. | Auxotrophe zellen zur virusproduktion sowie zusammensetzungen und verfahren zur herstellung |
| EP4314258A1 (de) | 2021-04-02 | 2024-02-07 | uniQure biopharma B.V. | Verfahren zur herstellung von einzelnen insektenzellklonen |
| CA3220866A1 (en) | 2021-06-02 | 2022-12-08 | - Anggakusuma | Insect cell production of parvoviral vectors with modified capsid proteins |
| AU2022298827A1 (en) * | 2021-06-23 | 2024-02-08 | Frontera Therapeutics, Inc. | Composition and method for treating hemophilia b |
| US20250297278A1 (en) | 2021-08-26 | 2025-09-25 | Uniqure Biopharma B.V. | Insect cell-produced high potency AAV vectors with CNS-tropism |
| CN113897396B (zh) * | 2021-09-18 | 2022-08-30 | 劲帆生物医药科技（武汉）有限公司 | 一种用于在昆虫细胞中表达包含重叠开放阅读框的基因的表达盒及其应用 |
| EP4426716A1 (de) | 2021-11-02 | 2024-09-11 | Voyager Therapeutics, Inc. | Aav-kapsidvarianten und verwendungen davon |
| CN114150021B (zh) | 2021-11-26 | 2022-10-28 | 劲帆生物医药科技（武汉）有限公司 | 一种包含重叠开放阅读框的基因的表达盒及其在昆虫细胞中的应用 |
| AU2022425534A1 (en) | 2021-12-30 | 2024-07-04 | Regel Therapeutics, Inc. | Compositions for modulating expression of sodium voltage-gated channel alpha subunit 1 and uses thereof |
| WO2023201207A1 (en) | 2022-04-11 | 2023-10-19 | Tenaya Therapeutics, Inc. | Adeno-associated virus with engineered capsid |
| US20250382637A1 (en) | 2022-06-21 | 2025-12-18 | Regel Therapeutics, Inc. | Genetic regulatory elements and uses thereof |
| WO2024047587A1 (en) | 2022-08-31 | 2024-03-07 | Regel Therapeutics, Inc. | Cas-phi compositions and methods of use |
| CN120077057A (zh) | 2022-10-04 | 2025-05-30 | 伊莱利利公司 | Trem2相关疾病和病症的基因治疗 |
| AR131035A1 (es) | 2022-11-11 | 2025-02-12 | Lilly Co Eli | Ácidos nucleicos sintéticos que incluyen constructos promotores dirigidos a astrocitos y métodos de uso de los mismos |
| WO2024218190A1 (en) | 2023-04-18 | 2024-10-24 | Uniqure Biopharma B.V. | Generation of adeno-associated virus capsid libraries for insect cells |
| JP2026518475A (ja) | 2023-05-26 | 2026-06-08 | リーゲル セラピューティクス インコーポレイティド | ナトリウム電位依存性チャネルアルファサブユニット２の発現を調節するための組成物及びその使用 |
| CN117070518A (zh) * | 2023-08-03 | 2023-11-17 | 劲帆生物医药科技（武汉）有限公司 | 一种用于表达包含重叠开放阅读框的基因的表达盒及应用 |
| WO2025025493A1 (zh) * | 2023-08-03 | 2025-02-06 | 劲帆生物医药科技（武汉）有限公司 | 一种含有重叠开放阅读框的表达盒及应用 |
| CN122438950A (zh) | 2023-10-17 | 2026-07-21 | 里格尔医疗股份有限公司 | 用于心肌组织表达的遗传调控元件及其用途 |
| WO2026017965A1 (en) | 2024-07-19 | 2026-01-22 | The University Court Of The University Of Edinburgh | Recombinant therapeutic fxn constructs and methods of treating friedreich ataxia and related conditions |
| WO2026043765A1 (en) | 2024-08-21 | 2026-02-26 | Eli Lilly And Company | Engineered regulatory splice elements for gene therapies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| WO1996017947A1 (en) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
| US5688676A (en) | 1995-06-07 | 1997-11-18 | Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| US5741683A (en) | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| CA2270285A1 (en) | 1996-12-18 | 1998-06-25 | Targeted Genetics Corporation | Aav split-packaging genes and cell lines comprising such genes for use in the production of recombinant aav vectors |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| WO2000024916A1 (en) | 1998-10-27 | 2000-05-04 | Crucell Holland B.V. | Improved aav vector production |
| DE19905501B4 (de) | 1999-02-10 | 2005-05-19 | MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie | Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels |
| EP1572893B1 (de) * | 2001-11-09 | 2009-01-07 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES | Produktion von adenoassoziiertem virus in insektenzellen |
| AU2004204462B2 (en) * | 2003-01-09 | 2012-03-08 | Macrogenics, Inc. | Dual expression vector system for antibody expression in bacterial and mammalian cells |
| CN1778812A (zh) * | 2004-11-24 | 2006-05-31 | 国家海洋环境监测中心 | 重组杆状病毒表达的诺瓦克样病毒衣壳蛋白及其制备方法 |
| WO2007084773A2 (en) | 2006-01-20 | 2007-07-26 | University Of North Carolina At Chapel Hill | Enhanced production of infectious parvovirus vectors in insect cells |
-
2007
- 2007-08-24 ES ES07814439T patent/ES2385679T3/es active Active
- 2007-08-24 CN CN2007800370312A patent/CN101522903B/zh active Active
- 2007-08-24 AT AT07814439T patent/ATE553206T1/de active
- 2007-08-24 US US12/297,958 patent/US8945918B2/en active Active
- 2007-08-24 EP EP07814439A patent/EP2061891B1/de active Active
- 2007-08-24 DK DK07814439.1T patent/DK2061891T3/da active
- 2007-08-24 WO PCT/US2007/076799 patent/WO2008024998A2/en not_active Ceased
-
2014
- 2014-06-05 US US14/297,165 patent/US20140329313A1/en not_active Abandoned
- 2014-10-03 US US14/505,847 patent/US9879279B2/en active Active
-
2016
- 2016-08-01 US US15/224,984 patent/US9879282B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101522903B (zh) | 2013-07-31 |
| DK2061891T3 (da) | 2012-07-23 |
| US20090203071A1 (en) | 2009-08-13 |
| US9879282B2 (en) | 2018-01-30 |
| US20150031115A1 (en) | 2015-01-29 |
| WO2008024998A3 (en) | 2008-11-06 |
| US20160333375A1 (en) | 2016-11-17 |
| EP2061891A2 (de) | 2009-05-27 |
| EP2061891A4 (de) | 2010-07-28 |
| US8945918B2 (en) | 2015-02-03 |
| CN101522903A (zh) | 2009-09-02 |
| US9879279B2 (en) | 2018-01-30 |
| WO2008024998A2 (en) | 2008-02-28 |
| EP2061891B1 (de) | 2012-04-11 |
| US20140329313A1 (en) | 2014-11-06 |
| ES2385679T3 (es) | 2012-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2061891T3 (da) | Ekspression i insektceller af gener med overlappende åbne læserammer, fremgangsmåder og sammensætninger hertil | |
| Zhu | Mammalian cell protein expression for biopharmaceutical production | |
| Zheng et al. | Metagenomic and metaproteomic insights into photoautotrophic and heterotrophic interactions in a Synechococcus culture | |
| EA201492202A1 (ru) | Способ экспрессии гетерологичных белков с использованием рекомбинантного вирусного вектора с минус-нитью рнк | |
| TR201806812T4 (tr) | Rna-yönlendirmeli hedef dna modifikasyonu için ve rna-yönlendirmeli transkripsiyon modifikasyonu için yöntemler ve bileşimler. | |
| WO2003102201A3 (en) | Methods and materials for the production of d-lactic acid in yeast | |
| WO2013049121A3 (en) | Recombinant phage and methods | |
| FI3536797T3 (fi) | Siirtogeenin tehostettu ilmentäminen ja prosessointi | |
| JP2008508886A5 (de) | ||
| ATE512980T1 (de) | Polypeptide mit beta-glucosidase-aktivität sowie diese codierende polynukleotide | |
| EP2379577A4 (de) | Zusammensetzungen und verfahren zur umprogrammierung von zellen ohne genetische modifikation | |
| JP2011182800A5 (de) | ||
| TN2014000069A1 (en) | Protein expression | |
| DK1805296T3 (da) | Stabil genomisk integrering af multipie polynukleotidkopier | |
| WO2014097113A3 (en) | Production of therapeutic proteins in genetically modified mammalian cells | |
| DK2431470T3 (da) | DNase expression i rekombinante værtsceller | |
| WO2011163531A3 (en) | Compositions and methods for re-programming cells without genetic modification for treatment of cardiovascular diseases | |
| DE602006019422D1 (de) | Verbesserte expressionselemente | |
| JP2009534036A5 (de) | ||
| AR090340A1 (es) | Operaciones de cosecha mejoradas para proteinas recombinadas | |
| WO2012028961A3 (en) | Compositions and methods for treating friedreich's ataxia with interferon gamma | |
| JP2013505701A5 (de) | ||
| ATE524563T1 (de) | System zur herstellung synthetischer promotoren | |
| ATE532861T1 (de) | Expressionsvektor | |
| DE60135325D1 (de) | Bakteriocin gegen listeria |